Prospective of curcumin, a pleiotropic signalling molecule from Curcuma longa in the treatment of Glioblastoma

European Journal of Medicinal Chemistry

Volumn 109, Issue , 2016, Pages 23-35

  Luthra, Pratibha Mehta ^a   Lal, Neetika ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

Apoptosis; Curcumin; GBM; Pharmacokinetics; Treatment

Indexed keywords

CAMPTOTHECIN; CISPLATIN; CURCUMIN; CYCLIN B1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; ETOPOSIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NUCLEAR FACTOR I; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; RAS PROTEIN; STAT3 PROTEIN; TENOFOVIR 3 HEXADECYLOXYPROPYL ESTER; TRANSCRIPTION FACTOR EGR 1; TRANSCRIPTION FACTOR ELK 1; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AUTOPHAGY; CANCER SURVIVAL; CANCER THERAPY; CELL CYCLE ARREST; CELL DEATH; CELL INVASION; CURCUMA LONGA; CYTOTOXICITY; DEACETYLATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; GENOME ANALYSIS; GLIOBLASTOMA; GLIOMA CELL; HISTONE ACETYLATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NEUROMODULATION; PLEIOTROPY; PROSPECTIVE STUDY; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; BRAIN NEOPLASMS; CHEMISTRY; CURCUMA; DRUG EFFECTS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BRAIN; BRAIN NEOPLASMS; CURCUMA; CURCUMIN; GLIOBLASTOMA; HUMANS;

EID: 84953285402     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.11.049     Document Type: Review

References (132)

1. H. Ohgaki, P. Kleihues, Genetic pathways to primary and secondary glioblastoma, Am. J. Pathol. 170 (2007) 1445-1453.
2. H. Ohgaki, P. Dessen, B. Jourde, S. Horstmann, T. Nishikawa, P.L. Di Patre, C. Burkhard, D. Schuler, N.M. Probst-Hensch, P.C. Maiorka, N. Baeza, P. Pisani, Y. Yonekawa, M.G. Yasargil, U.M. Lutolf, P. Kleihues, Genetic pathways to glioblastoma: a population-based study, Cancer Res. 64 (2004) 6892-6899.
3. B.K. Rasheed, R.N. Wiltshire, S.H. Bigner, D.D. Bigner, Molecular pathogenesis of malignant gliomas, Curr. Opin. Oncol. 11 (1999) 162-167.
4. H. Yan, D.W. Parsons, G. Jin, R. McLendon, B.A. Rasheed, W. Yuan, I. Kos, I. Batinic-Haberle, S. Jones, G.J. Riggins, H. Friedman, A. Friedman, D. Reardon, J. Herndon, K.W. Kinzler, V.E. Velculescu, B. Vogelstein, D.D. Bigner, IDH1 and IDH2 mutations in gliomas, N. Engl. J. Med. 360 (2009) 765-773.
5. R.Y. Bai, V. Staedtke, G.J. Riggins, Molecular targeting of glioblastoma: drug discovery and therapies, Trends Mol. Med. 17 (2011) 301-312.
6. S.K. Marie, S.M. Shinjo, Metabolism and brain cancer, Clinics (Sao Paulo) 66 (Suppl. 1) (2011) 33-43.
7. K. Oda, Y. Matsuoka, A. Funahashi, H. Kitano, A comprehensive pathway map of epidermal growth factor receptor signaling, Mol. Syst. Biol. 1 (2005), 2005 0010.
8. M. Nakada, D. Kita, T. Watanabe, Y. Hayashi, L. Teng, I.V. Pyko, J. Hamada, Aberrant signaling pathways in glioma, Cancers (Basel) 3 (2011) 3242-3278.
9. A. Barthel, S.T. Okino, J. Liao, K. Nakatani, J. Li, J.P. Whitlock Jr., R.A. Roth, Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1, J. Biol. Chem. 274 (1999) 20281-20286.
10. P.L. Pedersen, Warburg, me and Hexokinase 2: multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen, J. Bioenerg. Biomembr. 39 (2007) 211-222.
11. R.J. DeBerardinis, A. Mancuso, E. Daikhin, I. Nissim, M. Yudkoff, S. Wehrli, C.B. Thompson, Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 19345-19350.
12. F. Schwartzenberg-Bar-Yoseph, M. Armoni, E. Karnieli, The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression, Cancer Res. 64 (2004) 2627-2633.
13. K. Kawauchi, K. Araki, K. Tobiume, N. Tanaka, p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation, Nat. Cell Biol. 10 (2008) 611-618.
14. M. Akram, Citric acid cycle and role of its intermediates in metabolism, Cell Biochem. Biophys. 68 (2014) 475-478.
15. C. Frezza, D.A. Tennant, E. Gottlieb, IDH1 mutations in gliomas: when an enzyme loses its grip, Cancer Cell 17 (2010) 7-9.
16. C.B. Thompson, Metabolic enzymes as oncogenes or tumor suppressors, N. Engl. J. Med. 360 (2009) 813-815.
17. S. Zhao, Y. Lin, W. Xu, W. Jiang, Z. Zha, P. Wang, W. Yu, Z. Li, L. Gong, Y. Peng, J. Ding, Q. Lei, K.L. Guan, Y. Xiong, Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha, Science 324 (2009) 261-265.
18. L. Dang, D.W. White, S. Gross, B.D. Bennett, M.A. Bittinger, E.M. Driggers, V.R. Fantin, H.G. Jang, S. Jin, M.C. Keenan, K.M. Marks, R.M. Prins, P.S. Ward, K.E. Yen, L.M. Liau, J.D. Rabinowitz, L.C. Cantley, C.B. Thompson, M.G. Vander Heiden, S.M. Su, Cancer-associated IDH1 mutations produce 2-hydroxyglutarate, Nature 462 (2009) 739-744.
19. S.M. Lee, H.J. Koh, D.C. Park, B.J. Song, T.L. Huh, J.W. Park, Cytosolic NADP(+)- dependent isocitrate dehydrogenase status modulates oxidative damage to cells, Free Radic. Biol. Med. 32 (2002) 1185-1196.
20. S.C. Williams, M.A. Karajannis, L. Chiriboga, J.G. Golfinos, A. von Deimling, D. Zagzag, R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1alpha upregulation in adult glioma, Acta Neuropathol. 121 (2011) 279-281.
21. Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature 455 (2008) 1061-1068.
22. C.W. Brennan, R.G. Verhaak, A. McKenna, B. Campos, H. Noushmehr, S.R. Salama, S. Zheng, D. Chakravarty, J.Z. Sanborn, S.H. Berman, R. Beroukhim, B. Bernard, C.J. Wu, G. Genovese, I. Shmulevich, J. Barnholtz-Sloan, L. Zou, R. Vegesna, S.A. Shukla, G. Ciriello, W.K. Yung, W. Zhang, C. Sougnez, T. Mikkelsen, K. Aldape, D.D. Bigner, E.G. Van Meir, M. Prados, A. Sloan, K.L. Black, J. Eschbacher, G. Finocchiaro, W. Friedman, D.W. Andrews, A. Guha, M. Iacocca, B.P. O'Neill, G. Foltz, J. Myers, D.J. Weisenberger, R. Penny, R. Kucherlapati, C.M. Perou, D.N. Hayes, R. Gibbs, M. Marra, G.B. Mills, E. Lander, P. Spellman, R. Wilson, C. Sander, J. Weinstein, M. Meyerson, S. Gabriel, P.W. Laird, D. Haussler, G. Getz, L. Chin, The somatic genomic landscape of glioblastoma, Cell 155 (2013) 462-477.
23. T.A. Dolecek, J.M. Propp, N.E. Stroup, C. Kruchko, CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009, Neuro. Oncol. 14 (Suppl. 15) (2012) v1-49.
24. Bangalore, India, Consolidated Report of the HBCRs: 2001-2003. Source: National Cancer Registry Programme, Indian Council of Medical Research, April 2007.
25. C. Adamson, O.O. Kanu, A.I. Mehta, C. Di, N. Lin, A.K. Mattox, D.D. Bigner, Glioblastoma multiforme: a review of where we have been and where we are going, Expert Opin. Investig. Drugs 18 (2009) 1061-1083.
26. G. Prasad, D.A. Haas-Kogan, Radiation-induced gliomas, Expert Rev. Neurother. 9 (2009) 1511-1517.
27. M.M. Mrugala, Advances and challenges in the treatment of glioblastoma: a clinician's perspective, Discov. Med. 15 (2013) 221-230.
28. S. Oshiro, H. Tsugu, F. Komatsu, T. Ohmura, M. Ohta, S. Sakamoto, T. Fukushima, T. Inoue, Efficacy of temozolomide treatment in patients with high-grade glioma, Anticancer Res. 29 (2009) 911-917.
29. W.P. Roos, L.F. Batista, S.C. Naumann, W. Wick, M. Weller, C.F. Menck, B. Kaina, Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine, Oncogene 26 (2007) 186-197.
30. J.T. Kim, J.S. Kim, K.W. Ko, D.S. Kong, C.M. Kang, M.H. Kim, M.J. Son, H.S. Song, H.J. Shin, D.S. Lee, W. Eoh, D.H. Nam, Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas, Oncol. Rep. 16 (2006) 33-39.
31. R. Del Maestro, V. Siu, M. Seyed Sadr, J. Alshami, C. Sabau, E. Seyed Sadr, M. Guiot, A. Galarneau, J. Pouliot, K. Greaves, Safety and efficacy of presurgical neoadjuvant low-dose temozolomide in glioma patients, J. Clin. Oncol. 28 (2010) (suppl; abstr e12510^).
32. T. Fukushima, H. Takeshima, H. Kataoka, Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT, Anticancer Res. 29 (2009) 4845-4854.
33. M.R. Gilbert, J.J. Dignam, T.S. Armstrong, J.S. Wefel, D.T. Blumenthal, M.A. Vogelbaum, H. Colman, A. Chakravarti, S. Pugh, M. Won, R. Jeraj, P.D. Brown, K.A. Jaeckle, D. Schiff, V.W. Stieber, D.G. Brachman, M. Werner-Wasik, I.W. Tremont-Lukats, E.P. Sulman, K.D. Aldape, W.J. Curran Jr., M.P. Mehta, A randomized trial of bevacizumab for newly diagnosed glioblastoma, N. Engl. J. Med. 370 (2014) 699-708.
34. H.S. Poulsen, T. Urup, S.R. Michaelsen, M. Staberg, M. Villingshoj, U. Lassen, The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients, Cancer Manag. Res. 6 (2014) 373-387.
35. R. Soffietti, R. Ruda, E. Trevisan, New chemotherapy options for the treatment of malignant gliomas, Anticancer Drugs 18 (2007) 621-632.
36. C. Krakstad, M. Chekenya, Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics, Mol. Cancer 9 (2010) 135.
37. B.B. Aggarwal, S. Shishodia, Molecular targets of dietary agents for prevention and therapy of cancer, Biochem. Pharmacol. 71 (2006) 1397-1421.
38. E.P. Moiseeva, M.M. Manson, Dietary chemopreventive phytochemicals: too little or too much? Cancer Prev Res (Phila) 2 (2009) 611-616.
39. S. Ramos, Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways, Mol. Nutr. Food Res. 52 (2008) 507-526.
40. L.G. Korkina, C. De Luca, V.A. Kostyuk, S. Pastore, Plant polyphenols and tumors: from mechanisms to therapies, prevention, and protection against toxicity of anti-cancer treatments, Curr. Med. Chem. 16 (2009) 3943-3965.
41. I.T. Johnson, Phytochemicals and cancer, Proc. Nutr. Soc. 66 (2007) 207-215.
42. Y.J. Surh, Cancer chemoprevention with dietary phytochemicals, Nat. Rev. Cancer 3 (2003) 768-780.
43. A.B. Kunnumakkara, P. Anand, B.B. Aggarwal, Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins, Cancer Lett. 269 (2008) 199-225.
44. J.M. Witkin, X. Li, Curcumin, an active constituent of the ancient medicinal herb Curcuma longa L.: some uses and the establishment and biological basis of medical efficacy, CNS Neurol. Disord. Drug Targets 12 (2013) 487-497.
45. E. Balogun, M. Hoque, P. Gong, E. Killeen, C.J. Green, R. Foresti, J. Alam, R. Motterlini, Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element, Biochem. J. 371 (2003) 887-895.
46. J.S. Jurenka, Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research, Altern. Med. Rev. 14 (2009) 141-153.
47. R. De, P. Kundu, S. Swarnakar, T. Ramamurthy, A. Chowdhury, G.B. Nair, A.K. Mukhopadhyay, Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice, Antimicrob. Agents Chemother. 53 (2009) 1592-1597.
48. A. Duvoix, R. Blasius, S. Delhalle, M. Schnekenburger, F. Morceau, E. Henry, M. Dicato, M. Diederich, Chemopreventive and therapeutic effects of curcumin, Cancer Lett. 223 (2005) 181-190.
49. P. Yoysungnoen, P. Wirachwong, P. Bhattarakosol, H. Niimi, S. Patumraj, Antiangiogenic activity of curcumin in hepatocellular carcinoma cells implanted nude mice, Clin. Hemorheol. Microcirc. 33 (2005) 127-135.
50. B.B. Aggarwal, A. Kumar, A.C. Bharti, Anticancer potential of curcumin: preclinical and clinical studies, Anticancer Res. 23 (2003) 363-398.
51. M. Lopez-Lazaro, Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent, Mol. Nutr. Food. Res. 52 (Suppl. 11) (2008) S103-S127.
52. S. Gill, O. Pulido, Glutamate receptors in peripheral tissues: excitatory transmission outside the CNS, Kulwer Academic/Plenum Publishers, New York, 2005. Reference to a chapter in an edited book.
53. S.C. Gupta, S. Patchva, B.B. Aggarwal, Therapeutic roles of curcumin: lessons learned from clinical trials, AAPS J. 15 (2013) 195-218.
54. K.J. Hatanpaa, S. Burma, D. Zhao, A.A. Habib, Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance, Neoplasia 12 (2010) 675-684.
55. A.A. Habib, S.J. Chun, B.G. Neel, T. Vartanian, Increased expression of epidermal growth factor receptor induces sequestration of extracellular signal-related kinases and selective attenuation of specific epidermal growth factor-mediated signal transduction pathways, Mol. Cancer Res. 1 (2003) 219-233.
56. C.C. Su, M.J. Wang, T.L. Chiu, The anti-cancer efficacy of curcumin scrutinized through core signaling pathways in glioblastoma, Int. J. Mol. Med. 26 (2010) 217-224.
57. B.H. Choi, C.G. Kim, Y.S. Bae, Y. Lim, Y.H. Lee, S.Y. Shin, p21 Waf1/Cip1 expression by curcumin in U-87MG human glioma cells: role of early growth response-1 expression, Cancer Res. 68 (2008) 1369-1377.
58. A. Zanotto-Filho, E. Braganhol, M.I. Edelweiss, G.A. Behr, R. Zanin, R. Schroder, A. Simoes-Pires, A.M. Battastini, J.C. Moreira, The curry spice curcumin selectively inhibits cancer cells growth in vitro and in preclinical model of glioblastoma, J. Nutr. Biochem. 23 (2012) 591-601.
59. Y. Mebratu, Y. Tesfaigzi, How ERK1/2 activation controls cell proliferation and cell death: is subcellular localization the answer? Cell Cycle 8 (2009) 1168-1175.
60. S. Zhuang, R.G. Schnellmann, A death-promoting role for extracellular signalregulated kinase, J. Pharmacol. Exp. Ther. 319 (2006) 991-997.
61. X. Deschenes-Simard, F. Kottakis, S. Meloche, G. Ferbeyre, ERKs in cancer: friends or foes? Cancer Res. 74 (2014) 412-419.
62. Z. Lu, S. Xu, ERK1/2 MAP kinases in cell survival and apoptosis, IUBMB Life 58 (2006) 621-631.
63. K. Ghoreschi, A. Laurence, J.J. O'Shea, Janus kinases in immune cell signaling, Immunol. Rev. 228 (2009) 273-287.
64. D.A. Harrison, The Jak/STAT pathway, Cold Spring Harb. Perspect. Biol. 4 (2012).
65. A. Xiong, Z. Yang, Y. Shen, J. Zhou, Q. Shen, Transcription factor STAT3 as a novel molecular target for cancer prevention, Cancers (Basel) 6 (2014) 926-957.
66. J.E. Kim, M. Patel, J. Ruzevick, C.M. Jackson, M. Lim, STAT3 activation in glioblastoma: biochemical and therapeutic implications, Cancers (Basel) 6 (2014) 376-395.
67. S.O. Rahaman, P.C. Harbor, O. Chernova, G.H. Barnett, M.A. Vogelbaum, S.J. Haque, Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells, Oncogene 21 (2002) 8404-8413.
68. C. Senft, M. Polacin, M. Priester, V. Seifert, D. Kogel, J. Weissenberger, The nontoxic natural compound Curcumin exerts anti-proliferative, anti-migratory, and anti-invasive properties against malignant gliomas, BMC Cancer 10 (2010) 491.
69. J.A. Engelman, J. Luo, L.C. Cantley, The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism, Nat. Rev. Genet. 7 (2006) 606-619.
70. H. Mao, D.G. Lebrun, J. Yang, V.F. Zhu, M. Li, Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets, Cancer Invest. 30 (2012) 48-56.
71. H. Wang, W. Zhang, H.J. Huang, W.S. Liao, G.N. Fuller, Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas, Lab. Invest 84 (2004) 941-951.
72. I. Sansal, W.R. Sellers, The biology and clinical relevance of the PTEN tumor suppressor pathway, J. Clin. Oncol. 22 (2004) 2954-2963.
73. K.M. Dhandapani, V.B. Mahesh, D.W. Brann, Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors, J. Neurochem. 102 (2007) 522-538.
74. B. Raychaudhuri, Y. Han, T. Lu, M.A. Vogelbaum, Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype, J. Neurooncol 85 (2007) 39-47.
75. H. Aoki, Y. Takada, S. Kondo, R. Sawaya, B.B. Aggarwal, Y. Kondo, Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signalregulated kinase signaling pathways, Mol. Pharmacol. 72 (2007) 29-39.
76. S. Nagai, M. Kurimoto, K. Washiyama, Y. Hirashima, T. Kumanishi, S. Endo, Inhibition of cellular proliferation and induction of apoptosis by curcumin in human malignant astrocytoma cell lines, J. Neurooncol 74 (2005) 105-111.
77. T.Y. Huang, T.H. Tsai, C.W. Hsu, Y.C. Hsu, Curcuminoids suppress the growth and induce apoptosis through caspase-3-dependent pathways in glioblastoma multiforme (GBM) 8401 cells, J. Agric. Food Chem. 58 (2010) 10639-10645.
78. E. Liu, J. Wu, W. Cao, J. Zhang, W. Liu, X. Jiang, X. Zhang, Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma, J. Neurooncol 85 (2007) 263-270.
79. M.J. Park, E.H. Kim, I.C. Park, H.C. Lee, S.H. Woo, J.Y. Lee, Y.J. Hong, C.H. Rhee, S.H. Choi, B.S. Shim, S.H. Lee, S.I. Hong, Curcumin inhibits cell cycle progression of immortalized human umbilical vein endothelial (ECV304) cells by up-regulating cyclin-dependent kinase inhibitor, p21WAF1/CIP1, p27KIP1 and p53, Int. J. Oncol. 21 (2002) 379-383.
80. M. Nakada, Y. Okada, J. Yamashita, The role of matrix metalloproteinases in glioma invasion, Front. Biosci. 8 (2003) e261-269.
81. S. Lorenzl, D.S. Albers, J.W. Chirichigno, S.J. Augood, M.F. Beal, Elevated levels of matrix metalloproteinases-9 and -1 and of tissue inhibitors of MMPs, TIMP-1 and TIMP-2 in postmortem brain tissue of progressive supranuclear palsy, J. Neurol. Sci. 218 (2004) 39-45.
82. J. Mercapide, R. Lopez De Cicco, J.S. Castresana, A.J. Klein-Szanto, Stromelysin-1/matrix metalloproteinase-3 (MMP-3) expression accounts for invasive properties of human astrocytoma cell lines, Int. J. Cancer 106 (2003) 676-682.
83. D. Koul, R. Parthasarathy, R. Shen, M.A. Davies, S.A. Jasser, S.K. Chintala, J.S. Rao, Y. Sun, E.N. Benvenisite, T.J. Liu, W.K. Yung, Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN, Oncogene 20 (2001) 6669-6678.
84. M.J. Park, M.S. Kim, I.C. Park, H.S. Kang, H. Yoo, S.H. Park, C.H. Rhee, S.I. Hong, S.H. Lee, PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation, Cancer Res. 62 (2002) 6318-6322.
85. R. Sawaya, Y. Go, A.P. Kyritisis, J. Uhm, B. Venkaiah, S. Mohanam, Z.L. Gokaslan, J.S. Rao, Elevated levels of Mr 92,000 type IV collagenase during tumor growth in vivo, Biochem. Biophys. Res. Commun. 251 (1998) 632-636.
86. S.Y. Kim, S.H. Jung, H.S. Kim, Curcumin is a potent broad spectrum inhibitor of matrix metalloproteinase gene expression in human astroglioma cells, Biochem. Biophys. Res. Commun. 337 (2005) 510-516.
87. M.S. Woo, S.H. Jung, S.Y. Kim, J.W. Hyun, K.H. Ko, W.K. Kim, H.S. Kim, Curcumin suppresses phorbol ester-induced matrix metalloproteinase-9 expression by inhibiting the PKC to MAPK signaling pathways in human astroglioma cells, Biochem. Biophys. Res. Commun. 335 (2005) 1017-1025.
88. J.W. Shay, W.E. Wright, Senescence and immortalization: role of telomeres and telomerase, Carcinogenesis 26 (2005) 867-874.
89. Z.G. Dikmen, T. Ozgurtas, S.M. Gryaznov, B.S. Herbert, Targeting critical steps of cancer metastasis and recurrence using telomerase template antagonists, Biochim. Biophys. Acta 1792 (2009) 240-247.
90. V.G. Sekaran, J. Soares, M.B. Jarstfer, Structures of telomerase subunits provide functional insights, Biochim. Biophys. Acta 1804 (2010) 1190-1201.
91. G. Aubert, P.M. Lansdorp, Telomeres and aging, Physiol. Rev. 88 (2008) 557-579.
92. J.W. Shay, W.E. Wright, Telomeres and telomerase: implications for cancer and aging, Radiat. Res. 155 (2001) 188-193.
93. A.K. Khaw, M.P. Hande, G. Kalthur, Curcumin inhibits telomerase and induces telomere shortening and apoptosis in brain tumour cells, J. Cell Biochem. 114 (2013) 1257-1270.
94. S. Ropero, M. Esteller, The role of histone deacetylases (HDACs) in human cancer, Mol. Oncol. 1 (2007) 19-25.
95. C.J. Fry, C.L. Peterson, Transcription. Unlocking the gates to gene expression, Science 295 (2002) 1847-1848.
96. S.Y. Archer, R.A. Hodin, Histone acetylation and cancer, Curr. Opin. Genet. Dev. 9 (1999) 171-174.
97. A. Klochendler-Yeivin, M. Yaniv, Chromatin modifiers and tumor suppression, Biochim. Biophys. Acta 1551 (2001) M1-M10.
98. S.K. Kang, S.H. Cha, H.G. Jeon, Curcumin-induced histone hypoacetylation enhances caspase-3-dependent glioma cell death and neurogenesis of neural progenitor cells, Stem Cells Dev. 15 (2006) 165-174.
99. P.M. Luthra, R. Kumar, A. Prakash, Demethoxycurcumin induces Bcl-2 mediated G2/M arrest and apoptosis in human glioma U87 cells, Biochem. Biophys. Res. Commun. 384 (2009) 420-425.
100. R. Kim, Recent advances in understanding the cell death pathways activated by anticancer therapy, Cancer 103 (2005) 1551-1560.
101. T.G. Cotter, Apoptosis and cancer: the genesis of a research field, Nat. Rev. Cancer 9 (2009) 501-507.
102. A. Thorburn, Death receptor-induced cell killing, Cell Signal 16 (2004) 139-144.
103. D.R. Green, Apoptotic pathways: paper wraps stone blunts scissors, Cell 102 (2000) 1-4.
104. Y. Tsujimoto, S. Shimizu, Role of the mitochondrial membrane permeability transition in cell death, Apoptosis 12 (2007) 835-840.
105. Y. Tsujimoto, Cell death regulation by the Bcl-2 protein family in the mitochondria, J. Cell Physiol. 195 (2003) 158-167.
106. A. Kunwar, A. Barik, B. Mishra, K. Rathinasamy, R. Pandey, K.I. Priyadarsini, Quantitative cellular uptake, localization and cytotoxicity of curcumin in normal and tumor cells, Biochim. Biophys. Acta 1780 (2008) 673-679.
107. C. Syng-Ai, A.L. Kumari, A. Khar, Effect of curcumin on normal and tumor cells: role of glutathione and bcl-2, Mol. Cancer Ther. 3 (2004) 1101-1108.
108. S. Reuter, S. Eifes, M. Dicato, B.B. Aggarwal, M. Diederich, Modulation of antiapoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells, Biochem. Pharmacol. 76 (2008) 1340-1351.
109. S. Karmakar, N.L. Banik, S.J. Patel, S.K. Ray, Curcumin activated both receptormediated and mitochondria-mediated proteolytic pathways for apoptosis in human glioblastoma T98G cells, Neurosci. Lett. 407 (2006) 53-58.
110. S. Karmakar, N.L. Banik, S.K. Ray, Curcumin suppressed anti-apoptotic signals and activated cysteine proteases for apoptosis in human malignant glioblastoma U87MG cells, Neurochem. Res. 32 (2007) 2103-2113.
111. Z.J. Yang, C.E. Chee, S. Huang, F.A. Sinicrope, The role of autophagy in cancer: therapeutic implications, Mol. Cancer Ther. 10 (2011) 1533-1541.
112. W. Zhuang, L. Long, B. Zheng, W. Ji, N. Yang, Q. Zhang, Z. Liang, Curcumin promotes differentiation of glioma-initiating cells by inducing autophagy, Cancer Sci. 103 (2012) 684-690.
113. N. Chen, V. Karantza-Wadsworth, Role and regulation of autophagy in cancer, Biochim. Biophys. Acta 1793 (2009) 1516-1523.
114. E. Morselli, L. Galluzzi, O. Kepp, J.M. Vicencio, A. Criollo, M.C. Maiuri, G. Kroemer, Anti- and pro-tumor functions of autophagy, Biochim. Biophys. Acta 1793 (2009) 1524-1532.
115. S. Purkayastha, A. Berliner, S.S. Fernando, B. Ranasinghe, I. Ray, H. Tariq, P. Banerjee, Curcumin blocks brain tumor formation, Brain Res. 1266 (2009) 130-138.
116. M.C. Perry, M. Demeule, A. Regina, R. Moumdjian, R. Beliveau, Curcumin inhibits tumor growth and angiogenesis in glioblastoma xenografts, Mol. Nutr. Food Res. 54 (2010) 1192-1201.
117. M. Hossain, N.L. Banik, S.K. Ray, Synergistic anti-cancer mechanisms of curcumin and paclitaxel for growth inhibition of human brain tumor stem cells and LN18 and U138MG cells, Neurochem. Int. 61 (2012) 1102-1113.
118. D. Merino, N. Lalaoui, A. Morizot, E. Solary, O. Micheau, TRAIL in cancer therapy: present and future challenges, Expert Opin. Ther. Targets 11 (2007) 1299-1314.
119. X. Gao, D. Deeb, H. Jiang, Y.B. Liu, S.A. Dulchavsky, S.C. Gautam, Curcumin differentially sensitizes malignant glioma cells to TRAIL/Apo2L-mediated apoptosis through activation of procaspases and release of cytochrome c from mitochondria, J. Exp. Ther. Oncol. 5 (2005) 39-48.
120. M. Mimeault, S.K. Batra, Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy, Chin. Med. 6 (2011) 31.
121. D. Eigner, D. Scholz, Ferula asa-foetida and Curcuma longa in traditional medical treatment and diet in Nepal, J. Ethnopharmacol. 67 (1999) 1-6.
122. C.D. Lao, M.T.t. Ruffin, D. Normolle, D.D. Heath, S.I. Murray, J.M. Bailey, M.E. Boggs, J. Crowell, C.L. Rock, D.E. Brenner, Dose escalation of a curcuminoid formulation, BMC Complement. Altern. Med. 6 (2006) 10.
123. P.R. Holt, S. Katz, R. Kirshoff, Curcumin therapy in inflammatory bowel disease: a pilot study, Dig. Dis. Sci. 50 (2005) 2191-2193.
124. A.L. Cheng, C.H. Hsu, J.K. Lin, M.M. Hsu, Y.F. Ho, T.S. Shen, J.Y. Ko, J.T. Lin, B.R. Lin, W. Ming-Shiang, H.S. Yu, S.H. Jee, G.S. Chen, T.M. Chen, C.A. Chen, M.K. Lai, Y.S. Pu, M.H. Pan, Y.J. Wang, C.C. Tsai, C.Y. Hsieh, Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions, Anticancer Res. 21 (2001) 2895-2900.
125. R.A. Sharma, S.A. Euden, S.L. Platton, D.N. Cooke, A. Shafayat, H.R. Hewitt, T.H. Marczylo, B. Morgan, D. Hemingway, S.M. Plummer, M. Pirmohamed, A.J. Gescher, W.P. Steward, Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance, Clin. Cancer Res. 10 (2004) 6847-6854.
126. P. Anand, A.B. Kunnumakkara, R.A. Newman, B.B. Aggarwal, Bioavailability of curcumin: problems and promises, Mol. Pharm. 4 (2007) 807-818.
127. R.A. Sharma, A.J. Gescher, W.P. Steward, Curcumin: the story so far, Eur. J. Cancer 41 (2005) 1955-1968.
128. G. Shoba, D. Joy, T. Joseph, M. Majeed, R. Rajendran, P.S. Srinivas, Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers, Planta Med. 64 (1998) 353-356.
129. S.K. Vareed, M. Kakarala, M.T. Ruffin, J.A. Crowell, D.P. Normolle, Z. Djuric, D.E. Brenner, Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects, Cancer Epidemiol. Biomark. Prev. 17 (2008) 1411-1417.
130. R.A. Sharma, H.R. McLelland, K.A. Hill, C.R. Ireson, S.A. Euden, M.M. Manson, M. Pirmohamed, L.J. Marnett, A.J. Gescher, W.P. Steward, Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer, Clin. Cancer Res. 7 (2001) 1894-1900.
131. G. Garcea, D.J. Jones, R. Singh, A.R. Dennison, P.B. Farmer, R.A. Sharma, W.P. Steward, A.J. Gescher, D.P. Berry, Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration, Br. J. Cancer 90 (2004) 1011-1015.
132. G. Garcea, D.P. Berry, D.J. Jones, R. Singh, A.R. Dennison, P.B. Farmer, R.A. Sharma, W.P. Steward, A.J. Gescher, Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences, Cancer Epidemiol. Biomark. Prev. 14 (2005) 120-125.